Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
ScPharmaceuticals: The Third Time's A Charm
09:11am, Wednesday, 12'th May 2021
ScPharmaceuticals: The Third Time's A Charm
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
07:30am, Wednesday, 12'th May 2021
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring m
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results
07:30am, Friday, 07'th May 2021
– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 –
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic
Verrica Announces Pricing of Public Offering of Common Stock
09:31pm, Monday, 22'nd Mar 2021
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
07:30am, Wednesday, 03'rd Mar 2021
WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
07:30am, Tuesday, 23'rd Feb 2021
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring
- PDUFA goal date assigned is June 23, 2021 -
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new m
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
04:01pm, Wednesday, 23'rd Dec 2020
WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring
- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - - Verrica reaffirms expectation to resubmit its New Drug A
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
04:05pm, Thursday, 12'th Nov 2020
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring
- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) -
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results
07:30am, Monday, 09'th Nov 2020
- Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 -
